Literature DB >> 32259917

Fibrostenotic strictures in Crohn's disease.

Jun Hwan Yoo1, Stefan Holubar2, Florian Rieder3.   

Abstract

The use of biologic agents including anti-tumor necrosis factor monoclonal antibodies followed by anti-integrins and anti-interleukins has drastically changed the treatment paradigm of Crohn's disease (CD) by improving clinical symptoms and mucosal healing. However, up to 70% of CD patients still eventually undergo surgery mainly due to fibrostenotic strictures. There are no specific anti-fibrotic drugs yet. This review comprehensively addresses the mechanism, prediction, diagnosis and treatment of the fibrostenotic strictures in CD. We also introduce promising anti-fibrotic agents which may be available in the near future and summarize challenges in developing novel therapies to treat fibrostenotic strictures in CD.

Entities:  

Keywords:  Crohn disease; Endoscopic balloon dilatation; Fibrostenosis; Intestinal fibrosis; Stricture

Year:  2020        PMID： 32259917     DOI： 10.5217/ir.2019.09148

Source DB:  PubMed          Journal:  Intest Res        ISSN： 1598-9100


  10 in total

1.  Network Pharmacology-Based Strategy to Identify the Pharmacological Mechanisms of Pulsatilla Decoction against Crohn's Disease.

Authors:  Jinguo Liu; Lu Zhang; Zhaojun Wang; Shanshan Chen; Shuyan Feng; Yujin He; Shuo Zhang
Journal:  Front Pharmacol       Date:  2022-04-05       Impact factor: 5.988

2.  Is radiological healing alone enough? 'Can't take my eyes off' the mucosa.

Authors:  Su Hyun Park; Sang Hyoung Park
Journal:  Korean J Intern Med       Date:  2022-04-28       Impact factor: 3.165

3.  Is Paradigm for the Role of Balloon-Assisted Enteroscopy Changing in Crohn's Disease?

Authors:  Yoo Jin Lee
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

Review 4.  Revisiting fibrosis in inflammatory bowel disease: the gut thickens.

Authors:  Silvia D'Alessio; Federica Ungaro; Daniele Noviello; Sara Lovisa; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-12-07       Impact factor: 46.802

Review 5.  Novel mechanisms and clinical trial endpoints in intestinal fibrosis.

Authors:  Jie Wang; Sinan Lin; Jonathan Mark Brown; David van Wagoner; Claudio Fiocchi; Florian Rieder
Journal:  Immunol Rev       Date:  2021-05-16       Impact factor: 10.983

6.  Crohn's disease: a population-based study of surgery in the age of biological therapy.

Authors:  Christian Stöss; Maximilian Berlet; Stefan Reischl; Ulrich Nitsche; Marie-Christin Weber; Helmut Friess; Dirk Wilhelm; Philipp-Alexander Neumann
Journal:  Int J Colorectal Dis       Date:  2021-04-19       Impact factor: 2.571

7.  Diagnosis and Psychotherapeutic Needs by Early Maladaptive Schemas in Patients With Inflammatory Bowel Disease.

Authors:  Cornelia Rada; Dan Gheonea; Cristian George Ţieranu; Denisa Elena Popa
Journal:  Front Psychol       Date:  2022-02-09

8.  Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn's Disease Recurrence.

Authors:  Jongwook Yu; Hye Kyung Hyun; Jihye Park; Eun Ae Kang; Soo Jung Park; Jae Jun Park; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Gut Liver       Date:  2022-05-13       Impact factor: 4.519

Review 9.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

10.  Clinical factors to predict flare-up in patients with inflammatory bowel disease during international air travel: A prospective study.

Authors:  Jihye Park; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Nayoung Kim; Dong Ho Lee
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.